Eli Lilly and Co (MIL:1LLY)
€ 733.1 -11.4 (-1.53%) Market Cap: 703.72 Bil Enterprise Value: 729.10 Bil PE Ratio: 87.15 PB Ratio: 50.94 GF Score: 66/100

Precision BioSciences Inc and Eli Lilly and Co In Vivo Gene Editing Collaboration - Conference Call Transcript

Nov 20, 2020 / 01:30PM GMT
Operator

Ladies and gentlemen, thank you for standing by and welcome to the Precision Biosciences In Vivo Gene Editing Collaboration with Lilly Conference Call.

(Operator Instructions)

I would now like to hand the conference over to you speaker today, Alex Kelly, Chief Corporate Affairs Officer. Please go ahead.

Alex Kelly
Precision BioSciences, Inc. - Chief Corporate Affairs Officer

Thank you and good morning everyone and welcome to the Precision BioSciences webcast to announce our genome editing research collaboration and license agreement with Eli Lilly.

I'm Alex Kelly and I'm the Chief Corporate Affairs Officer for Precision BioSciences. And before we begin, I'd like to remind you that some of the statements regarding Precision's future expectations, beliefs, intentions, goals, strategies, plans or prospects are considered forward-looking statements within meaning of the Private Securities Litigation Reform Act of 1995.

Forward-looking statements including without limitation statements regarding the expected benefits of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot